Enstamont F 180 Tablet is a combination medication containing Montelukast 10 mg and Fexofenadine 180 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Montelukast is a leukotriene receptor antagonist that inhibits the action of leukotrienes, substances in the body responsible for inflammation, bronchoconstriction, and mucus production in allergic responses. Fexofenadine is a second-generation antihistamine that selectively blocks peripheral H1 receptors, thereby alleviating symptoms such as sneezing, nasal congestion, runny nose, and itching without causing significant sedation. The synergistic effect of Montelukast and Fexofenadine provides comprehensive relief from both early and late-phase allergic reactions. Enstamont F 180 is indicated for patients who require effective control of moderate to severe allergic symptoms, particularly when monotherapy is insufficient. It is generally well-tolerated; however, patients should be monitored for potential side effects including headache, dizziness, gastrointestinal disturbances, and hypersensitivity reactions. This medication should be used under medical supervision, with dosage adjustments considered based on clinical response and patient-specific factors. Enstamont F 180 Tablet offers a convenient once-daily dosing regimen to enhance compliance and improve quality of life in individuals suffering from allergic disorders.